IN2014DN08982A - - Google Patents

Download PDF

Info

Publication number: IN2014DN08982A
Authority: IN; India
Prior art keywords: disease; duchene; hypertriglyceridemia; hypercholesterolemia; alzheimer
Prior art date: 2012-05-18

Application number

Other languages

English (en)

Inventor

Michel Bazinet

Andrew Vaillant

Original Assignee

Replicor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-18

Filing date

2013-05-17

Publication date

2015-05-22

2013-05-17 Application filed by Replicor Inc filed Critical Replicor Inc

2015-05-22 Publication of IN2014DN08982A publication Critical patent/IN2014DN08982A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Virology (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Zoology (AREA)
AIDS & HIV (AREA)
Wood Science & Technology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Obesity (AREA)

IN8982DEN2014 2012-05-18 2013-05-17 IN2014DN08982A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261648694P	2012-05-18	2012-05-18
PCT/CA2013/050378 WO2013170385A1 (fr)	2012-05-18	2013-05-17	Procédés à base de complexes chélatés oligonucléotidiques

Publications (1)

Publication Number	Publication Date
IN2014DN08982A true IN2014DN08982A (fr)	2015-05-22

Family

ID=49581827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN8982DEN2014 IN2014DN08982A (fr)	2012-05-18	2013-05-17

Country Status (37)

Country	Link
US (1)	US9616083B2 (fr)
EP (1)	EP2849760B1 (fr)
JP (2)	JP6294308B2 (fr)
KR (1)	KR101975915B1 (fr)
CN (1)	CN104379152B (fr)
AR (1)	AR091065A1 (fr)
AU (1)	AU2013262415B2 (fr)
BR (1)	BR112014028568B1 (fr)
CA (1)	CA2873526C (fr)
CL (1)	CL2014003135A1 (fr)
CO (1)	CO7131388A2 (fr)
CR (1)	CR20140522A (fr)
CU (1)	CU20140132A7 (fr)
CY (1)	CY1122856T1 (fr)
DK (1)	DK2849760T3 (fr)
DO (1)	DOP2014000263A (fr)
EA (1)	EA034799B1 (fr)
EC (1)	ECSP14027542A (fr)
ES (1)	ES2767333T3 (fr)
HR (1)	HRP20200045T1 (fr)
HU (1)	HUE047456T2 (fr)
IL (1)	IL235402B (fr)
IN (1)	IN2014DN08982A (fr)
LT (1)	LT2849760T (fr)
MX (1)	MX360626B (fr)
MY (1)	MY168209A (fr)
NZ (1)	NZ701931A (fr)
PH (1)	PH12014502484B1 (fr)
PL (1)	PL2849760T3 (fr)
PT (1)	PT2849760T (fr)
RS (1)	RS59914B1 (fr)
SG (1)	SG11201407261XA (fr)
SI (1)	SI2849760T1 (fr)
SM (1)	SMT202000025T1 (fr)
TW (1)	TWI648288B (fr)
WO (1)	WO2013170385A1 (fr)
ZA (1)	ZA201408082B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2203173E (pt)	2007-10-26	2016-03-15	Academisch Ziekenhuis Leiden	Resumo
EP2119783A1 (fr)	2008-05-14	2009-11-18	Prosensa Technologies B.V.	Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
CN112251436A (zh)	2012-01-27	2021-01-22	比奥马林技术公司	治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
KR102025679B1 (ko)	2012-08-30	2019-09-26	레플리코르 인코포레이티드	Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법
PL3166615T3 (pl) *	2014-07-10	2024-02-19	Replicor Inc.	Chelatowane tiofosforanowe polimery kwasu nukleinowego do zastosowania w połączeniu z inhibitorem polimerazy hbv do leczenia zakażeń wirusem zapalenia wątroby typu b i wirusem zapalenia wątroby typu d
MA42157A (fr)	2015-04-23	2018-02-28	Geron Corp	Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
EP4279084B1 (fr)	2015-10-28	2025-06-11	Vertex Pharmaceuticals Inc.	Matériaux et méthodes pour traiter la dystrophie musculaire de duchenne
KR20180095694A (ko)	2015-12-23	2018-08-27	퀸스랜드 유니버시티 오브 테크놀로지	핵산 올리고머 및 이의 용도
CN121271865A (zh) *	2016-07-05	2026-01-06	比奥马林技术公司	具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸
US11166976B2 (en)	2018-11-08	2021-11-09	Aligos Therapeutics, Inc.	S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (fr)	2021-04-30	2022-11-03	Tirmed Pharma Ab	Oligonucléotides monocaténaires pouvant être utilisés dans le traitement médical et/ou la prophylaxie d'infections virales

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2158834C (fr) *	1993-04-01	2004-12-07	Brenda F. Baker	Oligos antisens qui interferent avec l'activite de coiffe par la mrna et empechent la traduction
US20020166764A1 (en) *	1997-08-12	2002-11-14	University Of Southern California	Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) *	2002-02-20	2005-01-27	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1694959A (zh) *	2002-09-13	2005-11-09	雷普利瑟公司	非序列互补的抗病毒寡核苷酸
BR0314236A (pt) *	2002-09-13	2005-08-09	Replicor Inc	Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
CA2584207A1 (fr)	2004-10-19	2006-04-27	Replicor, Inc.	Oligonucleotides antiviraux
WO2007036016A1 (fr)	2005-09-29	2007-04-05	Replicor Inc.	Molécules thérapeutiques et leurs utilisations
US8101585B2 (en) *	2006-08-04	2012-01-24	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of JNK proteins
WO2009065181A1 (fr) *	2007-11-21	2009-05-28	Apollo Life Sciences Limited	Nanostructures appropriées à l'administration d'agents
US8404659B2 (en) *	2008-03-07	2013-03-26	Santaris Pharma A/S	Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2408796B1 (fr) *	2009-03-16	2020-04-22	Ionis Pharmaceuticals, Inc.	Ciblage de l'Apolipoprotéine B pour la réduction de l'apolipoprotéine C-III
CA2764683A1 (fr) *	2009-05-28	2010-12-02	Joseph Collard	Traitement de maladies associees a un gene antiviral grace a l'inhibition d'un produit de transcription antisens naturel d'un gene antiviral
CA2806616C (fr)	2010-08-20	2015-08-11	Replicor Inc.	Complexes chelates d'oligonucleotide

2013
- 2013-05-16 AR ARP130101695A patent/AR091065A1/es not_active Application Discontinuation
- 2013-05-17 BR BR112014028568-3A patent/BR112014028568B1/pt active IP Right Grant
- 2013-05-17 AU AU2013262415A patent/AU2013262415B2/en active Active
- 2013-05-17 CA CA2873526A patent/CA2873526C/fr active Active
- 2013-05-17 HR HRP20200045TT patent/HRP20200045T1/hr unknown
- 2013-05-17 IN IN8982DEN2014 patent/IN2014DN08982A/en unknown
- 2013-05-17 PL PL13791584T patent/PL2849760T3/pl unknown
- 2013-05-17 ES ES13791584T patent/ES2767333T3/es active Active
- 2013-05-17 LT LTEP13791584.9T patent/LT2849760T/lt unknown
- 2013-05-17 PT PT137915849T patent/PT2849760T/pt unknown
- 2013-05-17 JP JP2015511876A patent/JP6294308B2/ja not_active Expired - Fee Related
- 2013-05-17 EP EP13791584.9A patent/EP2849760B1/fr active Active
- 2013-05-17 CN CN201380025475.XA patent/CN104379152B/zh active Active
- 2013-05-17 KR KR1020147035251A patent/KR101975915B1/ko active Active
- 2013-05-17 SI SI201331646T patent/SI2849760T1/sl unknown
- 2013-05-17 MX MX2014013885A patent/MX360626B/es active IP Right Grant
- 2013-05-17 SM SM20200025T patent/SMT202000025T1/it unknown
- 2013-05-17 SG SG11201407261XA patent/SG11201407261XA/en unknown
- 2013-05-17 NZ NZ701931A patent/NZ701931A/en unknown
- 2013-05-17 RS RS20200065A patent/RS59914B1/sr unknown
- 2013-05-17 HU HUE13791584A patent/HUE047456T2/hu unknown
- 2013-05-17 US US13/896,427 patent/US9616083B2/en not_active Expired - Fee Related
- 2013-05-17 EA EA201401276A patent/EA034799B1/ru unknown
- 2013-05-17 MY MYPI2014003113A patent/MY168209A/en unknown
- 2013-05-17 DK DK13791584.9T patent/DK2849760T3/da active
- 2013-05-17 WO PCT/CA2013/050378 patent/WO2013170385A1/fr not_active Ceased
- 2013-05-17 TW TW102117593A patent/TWI648288B/zh active
2014
- 2014-10-30 IL IL235402A patent/IL235402B/en unknown
- 2014-11-04 ZA ZA2014/08082A patent/ZA201408082B/en unknown
- 2014-11-06 PH PH12014502484A patent/PH12014502484B1/en unknown
- 2014-11-14 CR CR20140522A patent/CR20140522A/es unknown
- 2014-11-17 EC ECIEPI201427542A patent/ECSP14027542A/es unknown
- 2014-11-17 CU CU2014000132A patent/CU20140132A7/es unknown
- 2014-11-18 DO DO2014000263A patent/DOP2014000263A/es unknown
- 2014-11-18 CL CL2014003135A patent/CL2014003135A1/es unknown
- 2014-11-19 CO CO14254326A patent/CO7131388A2/es unknown
2017
- 2017-11-02 JP JP2017212508A patent/JP2018058853A/ja active Pending
2020
- 2020-01-21 CY CY20201100051T patent/CY1122856T1/el unknown

Also Published As

Publication number	Publication date
PL2849760T3 (pl)	2020-05-18
LT2849760T (lt)	2020-04-10
MX360626B (es)	2018-11-12
DK2849760T3 (da)	2020-02-03
CA2873526C (fr)	2020-08-18
CO7131388A2 (es)	2014-12-01
CL2014003135A1 (es)	2015-01-09
ECSP14027542A (es)	2015-12-31
CR20140522A (es)	2014-12-10
IL235402B (en)	2022-01-01
EP2849760A4 (fr)	2015-03-25
US9616083B2 (en)	2017-04-11
CN104379152A (zh)	2015-02-25
CA2873526A1 (fr)	2013-11-21
JP2015517503A (ja)	2015-06-22
SI2849760T1 (sl)	2020-03-31
PT2849760T (pt)	2020-01-24
SMT202000025T1 (it)	2020-03-13
PH12014502484B1 (en)	2021-03-31
EA201401276A1 (ru)	2015-04-30
CU20140132A7 (es)	2015-02-26
SG11201407261XA (en)	2014-12-30
HRP20200045T1 (hr)	2020-03-20
BR112014028568A2 (pt)	2020-06-02
PH12014502484A1 (en)	2015-01-12
US20130310445A1 (en)	2013-11-21
KR101975915B1 (ko)	2019-05-08
HK1206259A1 (en)	2016-01-08
JP2018058853A (ja)	2018-04-12
TW201408689A (zh)	2014-03-01
ES2767333T3 (es)	2020-06-17
CN104379152B (zh)	2018-10-30
BR112014028568B1 (pt)	2022-02-15
AR091065A1 (es)	2014-12-30
WO2013170385A1 (fr)	2013-11-21
EA034799B1 (ru)	2020-03-23
EP2849760A1 (fr)	2015-03-25
CY1122856T1 (el)	2021-05-05
KR20150016330A (ko)	2015-02-11
AU2013262415A1 (en)	2014-11-27
AU2013262415B2 (en)	2017-06-22
TWI648288B (zh)	2019-01-21
NZ701931A (en)	2016-06-24
DOP2014000263A (es)	2015-01-31
MY168209A (en)	2018-10-15
ZA201408082B (en)	2015-12-23
IL235402A0 (en)	2014-12-31
MX2014013885A (es)	2015-05-08
RS59914B1 (sr)	2020-03-31
EP2849760B1 (fr)	2019-10-30
JP6294308B2 (ja)	2018-03-14
HUE047456T2 (hu)	2020-04-28

Publication	Publication Date	Title
IN2014DN08982A (fr)	2015-05-22
IL277470A (en)	2020-11-30	Manufacturing method for pharmaceutical preparations for the treatment of diseases caused by CFTR
SG10201703452PA (en)	2017-06-29	Pharmaceutical compositions for the treatment of cftr mediated diseases
MD4589B1 (ro)	2018-08-31	Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
PL2892563T3 (pl)	2019-04-30	Kompozycje farmaceutyczne do leczenia choroby alzheimera
SI2939665T1 (sl)	2019-08-30	Farmacevtska sestava za zdravljenje HIV infekcij
PH12014502551A1 (en)	2015-01-21	Oligonucleotide chelate complex-polypeptide compositions and methods
EP2969011A4 (fr)	2017-03-01	Nanothérapie rapidement adaptable visant à traiter les maladies infectieuses
PL2846774T3 (pl)	2017-07-31	Kompozycja farmaceutyczna do leczenia dystrofii mięśniowej Duchenne'a